| Literature DB >> 20864484 |
Rutger J van Bommel1, Hidekazu Tanaka, Victoria Delgado, Matteo Bertini, Carel Jan Willem Borleffs, Nina Ajmone Marsan, Johannes Holzmeister, Frank Ruschitzka, Martin J Schalij, Jeroen J Bax, John Gorcsan.
Abstract
AIMS: current criteria for cardiac resynchronization therapy (CRT) are restricted to patients with a wide QRS complex (>120 ms). Overall, only 30% of heart failure patients demonstrate a wide QRS complex, leaving the majority of heart failure patients without this treatment option. However, patients with a narrow QRS complex exhibit left ventricular (LV) mechanical dyssynchrony, as assessed with echocardiography. To further elucidate the possible beneficial effect of CRT in heart failure patients with a narrow QRS complex, this two-centre, non-randomized observational study focused on different echocardiographic parameters of LV mechanical dyssynchrony reflecting atrioventricular, interventricular and intraventricular dyssynchrony, and the response to CRT in these patients. METHODS ANDEntities:
Mesh:
Year: 2010 PMID: 20864484 PMCID: PMC3001589 DOI: 10.1093/eurheartj/ehq334
Source DB: PubMed Journal: Eur Heart J ISSN: 0195-668X Impact factor: 29.983
Patient characteristics (n = 123)
| Age (years) | 61 ± 11 |
| Men/women | 97/26 |
| Aetiology ( | |
| Ischaemic | 75 (61%) |
| Non-ischaemic | 48 (39%) |
| NYHA class III | 123 (100%) |
| 6 MWT (m) | 310 ± 100 |
| QoL score | 34 ± 19 |
| QRS duration (ms), 25th–75th percentiles | 106 (98–114) |
| PR interval (ms) | 176 ± 28 |
| Medication ( | |
| Diuretics | 116 (94%) |
| ACE-inhibitors/AII-blocker | 111 (90%) |
| Beta-blockers | 114 (93%) |
| Spironolactone | 75 (61%) |
| LVEDV (mL), 25th–75th percentiles | 189 (155–237) |
| LVESV (mL), 25th–75th percentiles | 141 (110–176) |
| LVEF (%) | 27 ± 7 |
| LVFT/RR (%) | 52 ± 7 |
| LPEI (ms) | 121 ± 20 |
| IVMD (ms), 25th–75th percentiles | 16 (7–28) |
| OWD (ms) | 81 ± 38 |
| ASPWD (ms), 25th–75th percentiles | 107 (57–179) |
6 MWT, 6 minute walk test; ACE, angiotensin-converting enzyme; ASPWD, anteroseptal to posterior wall delay; IVMD, interventricular mechanical delay; LPEI, left pre-ejection interval; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; LVFT/RR, left ventricular filling ratio; NYHA, New York Heart Association; OWD, opposing wall delay; QoL, quality of life.
Baseline dyssynchrony parameters in patients with a QRS duration >100 ms and patients with a QRS duration ≤100 ms
| Variable | QRS duration ≤100 ms ( | QRS duration >100 ms ( | |
|---|---|---|---|
| LVFT/RR (%) | 51 ± 7 | 53 ± 7 | 0.156 |
| LPEI (ms) | 115 ± 21 | 124 ± 20 | |
| IVMD (ms), 25th–75th percentiles | 15 (4–25) | 17 (9–30) | 0.081 |
| OWD (ms) | 67 ± 37 | 87 ± 37 | |
| ASPWD (ms), 25th–75th percentiles | 75 (43–121) | 122 (66–187) |
Bold indicates statistical significance P < 0.05.
Patient characteristics in cardiac resynchronization therapy responders and non-responders
| Variable | Responders ( | Non-responders ( | |
|---|---|---|---|
| Age (years) | 61 ± 11 | 60 ± 12 | 0.618 |
| Men/Women | 44/15 | 53/11 | 0.279 |
| Aetiology ( | 0.095 | ||
| Ischaemic | 31 (53%) | 44 (69%) | |
| Non-ischaemic | 28 (47%) | 20 (31%) | |
| QRS duration (ms), 25th–75th percentiles | 106 (100–112) | 106 (98–114) | 0.847 |
| Follow-up | 128 (112–148) | 140 (120–154) | 0.217 |
| Medication ( | |||
| Diuretics | 55 (93%) | 61 (95%) | 0.709 |
| ACE-inhibitors/AII-blocker | 54 (92%) | 57 (89%) | 0.765 |
| Beta-blockers | 57 (97%) | 57 (89%) | 0.167 |
| Spironolactone | 33 (56%) | 42 (66%) | 0.355 |
| LVEDV (mL), 25th–75th percentiles | 195 (160–246) | 188 (152–231) | 0.199 |
| Follow-up | 157 (127–199) | 208 (160–247) | |
| LVESV (mL), 25th–75th percentiles | 154 (113–182) | 139 (103–167) | 0.125 |
| Follow-up | 98 (74–136) | 151 (113–186) | |
| LVEF (%) | 26 ± 7 | 28 ± 8 | 0.250 |
| Follow-up | 38 ± 9 | 28 ± 8 | |
| LVFT/RR (%) | 53 ± 8 | 51 ± 7 | 0.142 |
| LPEI (ms) | 123 ± 22 | 119 ± 19 | 0.344 |
| IVMD (ms), 25th–75th percentiles | 23 (9–33) | 13 (6–21) | |
| OWD (ms) | 92 ± 39 | 70 ± 35 | |
| ASPWD (ms), 25th–75th percentiles | 146 (100–200) | 68 (36–110) | |
ACE, angiotensin-converting enzyme; ASPWD, anteroseptal to posterior wall delay; IVMD, interventricular mechanical delay; LPEI, left pre-ejection interval; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; LVFT/RR, left ventricular filling ratio; OWD, opposing wall delay.
Bold indicates statistical significance P < 0.05.